PER 2.50% 8.2¢ percheron therapeutics limited

Ann: Phase IIb study of ATL1102 in DMD completes recruitment, page-169

  1. 246 Posts.
    lightbulb Created with Sketch. 26
    https://www.linkedin.com/posts/parentprojectmd_pfizer-discontinues-development-of-investigational-activity-7224075311850688512-9KDd?

    "PPMD is disappointed to learn that Pfizer Inc. has officially discontinued development of the company’s investigational mini-dystrophin #genetherapy, fordadistrogene movaparvovec. With this termination, Pfizer is not currently active in the Duchenne treatment space, which is a devastating setback for our community."

    Luckily for Pfizer, there is a DMD drug developer looking to partner up at the moment...

    GLTAH
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.2¢
Change
0.002(2.50%)
Mkt cap ! $73.92M
Open High Low Value Volume
8.2¢ 8.7¢ 7.9¢ $122.1K 1.460M

Buyers (Bids)

No. Vol. Price($)
1 50000 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.6¢ 6250 1
View Market Depth
Last trade - 15.59pm 10/09/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.